Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Manufacturers' views on outcome-based agreements.
Barjestehvan Waalwijk van Doorn-Khosrovani S, Timmers L, Pisters-van Roy A, Gijzen J, Blijlevens NMA, Bloemendal H. Barjestehvan Waalwijk van Doorn-Khosrovani S, et al. Among authors: bloemendal h. J Mark Access Health Policy. 2021 Oct 29;9(1):1993593. doi: 10.1080/20016689.2021.1993593. eCollection 2021. J Mark Access Health Policy. 2021. PMID: 34745459 Free PMC article.
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, van Roy AAMGP, Timmers L, Ly Tran TH, de Boer JE, de Wit GF, Geurts BS, Gelderblom H, Verheul HMW, Blijlevens N, Wymenga ANM, Eskens FALM, Smit EF, Bloemendal HJ, Voest EE. Zeverijn LJ, et al. Among authors: bloemendal hj. Lancet Oncol. 2022 Feb;23(2):198-201. doi: 10.1016/S1470-2045(21)00707-5. Lancet Oncol. 2022. PMID: 35114116 No abstract available.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free PMC article.
New strategies in anti-vascular cancer therapy.
Bloemendal HJ, Logtenberg T, Voest EE. Bloemendal HJ, et al. Eur J Clin Invest. 1999 Sep;29(9):802-9. doi: 10.1046/j.1365-2362.1999.00534.x. Eur J Clin Invest. 1999. PMID: 10469169 Review.
Activated vitronectin as a target for anticancer therapy with human antibodies.
Bloemendal HJ, de Boer HC, Koop EA, van Dongen AJ, Goldschmeding R, Landman WJ, Logtenberg T, Gebbink MF, Voest EE. Bloemendal HJ, et al. Cancer Immunol Immunother. 2004 Sep;53(9):799-808. doi: 10.1007/s00262-004-0506-z. Epub 2004 Jun 10. Cancer Immunol Immunother. 2004. PMID: 15197494 Free PMC article.
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
van Dodewaard-de Jong JM, Bouman-Wammes EW, Bloemendal HJ, Verheul HMW, de Klerk JMH, van den Eertwegh AJM. van Dodewaard-de Jong JM, et al. Among authors: bloemendal hj. Clin Nucl Med. 2017 Jun;42(6):415-420. doi: 10.1097/RLU.0000000000001604. Clin Nucl Med. 2017. PMID: 28263212 Clinical Trial.
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, Oprea-Lager DE, Hoekstra OS, van den Berg HP, Los M, Beeker A, Jonker MA, O'Sullivan JM, Verheul HMW, van den Eertwegh AJM. van Dodewaard-de Jong JM, et al. Among authors: bloemendal hj. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1319-1327. doi: 10.1007/s00259-017-3673-9. Epub 2017 Apr 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 28421240 Clinical Trial.
439 results